| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $126,255 | 3 | 18 |
Sells | $2,715,431 | 14 | 82 |
| Saxena Nishant C | Chief Business Officer | 3 | $126,255 | 0 | $0 | $126,255 |
| Ben Yong | director | 0 | $0 | 1 | $15,683 | $-15,683 |
| Kung Winston | director | 0 | $0 | 1 | $16,033 | $-16,033 |
| Altmeyer Anne | director | 0 | $0 | 1 | $19,088 | $-19,088 |
| Hodgson Ian | Chief Operating Officer | 0 | $0 | 2 | $25,791 | $-25,791 |
| Jenkins John Kenneth | director | 0 | $0 | 1 | $37,986 | $-37,986 |
| Smethurst Dominic | Chief Medical Officer | 0 | $0 | 2 | $77,176 | $-77,176 |
| Moran Sean F. | Chief Financial Officer | 0 | $0 | 2 | $157,559 | $-157,559 |
| Cohen Yuval | Chief Executive Officer | 0 | $0 | 2 | $279,348 | $-279,348 |
| Cormorant Asset Management, LP | 10 percent owner | 0 | $0 | 2 | $2.09M | $-2.09M |
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The …
Over the last 12 months, insiders at Corbus Pharmaceuticals Holdings, Inc. have bought $126,255 and sold $2.72M worth of Corbus Pharmaceuticals Holdings, Inc. stock.
On average, over the past 5 years, insiders at Corbus Pharmaceuticals Holdings, Inc. have bought $17.95M and sold $1.6M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Saxena Nishant C (Chief Business Officer) — $126,255.
The last purchase of 2,600 shares for transaction amount of $25,036 was made by Saxena Nishant C (Chief Business Officer) on 2026‑08‑11.
| 2026-10-29 | Sale | Cormorant Asset Management, LP | Former 10% Owner | 425,000 2.1279% | $4.10 | $1.74M | -7.23% | |
| 2026-09-14 | Sale | Ben Yong | director | 2,000 0.01% | $7.84 | $15,683 | -34.10% | |
| 2026-08-11 | Saxena Nishant C | Chief Business Officer | 2,600 0.0142% | $9.63 | $25,036 | -23.66% | ||
| 2026-08-07 | Sale | Cohen Yuval | Chief Executive Officer | 17,000 0.0868% | $10.08 | $171,396 | -28.61% | |
| 2026-08-07 | Sale | Moran Sean F. | Chief Financial Officer | 12,000 0.0613% | $10.08 | $120,971 | -28.61% | |
| 2026-06-10 | Sale | Kung Winston | director | 2,026 0.0166% | $7.91 | $16,033 | +14.29% | |
| 2026-06-10 | Sale | Altmeyer Anne | director | 2,412 0.0198% | $7.91 | $19,088 | +14.29% | |
| 2026-06-10 | Sale | Jenkins John Kenneth | director | 4,800 0.0394% | $7.91 | $37,986 | +14.29% | |
| 2026-06-03 | Saxena Nishant C | Chief Business Officer | 9,000 0.0722% | $7.58 | $68,220 | +13.69% | ||
| 2026-06-02 | Saxena Nishant C | Chief Business Officer | 4,500 0.0349% | $7.33 | $32,999 | +10.34% | ||
| 2026-03-02 | Sale | Smethurst Dominic | Chief Medical Officer | 6,097 0.0471% | $8.30 | $50,601 | +8.14% | |
| 2026-02-17 | Sale | Hodgson Ian | Chief Operating Officer | 847 0.0066% | $7.38 | $6,253 | +19.41% | |
| 2026-02-13 | Sale | Cohen Yuval | Chief Executive Officer | 13,871 0.1139% | $7.78 | $107,952 | +18.78% | |
| 2026-02-13 | Sale | Moran Sean F. | Chief Financial Officer | 4,701 0.0386% | $7.78 | $36,588 | +18.78% | |
| 2026-02-03 | Sale | Smethurst Dominic | Chief Medical Officer | 3,285 0.0262% | $8.09 | $26,575 | +10.12% | |
| 2026-02-03 | Sale | Hodgson Ian | Chief Operating Officer | 2,415 0.0192% | $8.09 | $19,537 | +10.12% | |
| 2025-12-11 | Sale | Cormorant Asset Management, LP | 10 percent owner | 30,029 0.2829% | $11.46 | $344,012 | -11.16% | |
| 2025-10-20 | Sale | Altmeyer Anne | director | 1,060 0.0097% | $20.50 | $21,730 | -50.55% | |
| 2025-05-30 | Sale | Altmeyer Anne | director | 1,392 0.0111% | $7.25 | $10,096 | +27.29% | |
| 2025-05-30 | Sale | Jenkins John Kenneth | director | 2,783 0.0225% | $7.35 | $20,465 | +27.29% |
| Cormorant Asset Management, LP | Former 10% Owner | 1919971 9.9268% | $7.43M | 5 | 2 | <0.0001% |
| Cohen Yuval | Chief Executive Officer | 157316 0.8134% | $608,812.92 | 25 | 6 | +10.48% |
| Moran Sean F. | Chief Financial Officer | 84694 0.4379% | $327,765.78 | 45 | 9 | +30.87% |
| Saxena Nishant C | Chief Business Officer | 77900 0.4028% | $301,473.00 | 3 | 0 | |
| Jenkins John Kenneth | director | 3833 0.0198% | $14,833.71 | 1 | 2 | <0.0001% |
| Tepper Mark | President and CSO | 2101000 10.8628% | $8.13M | 1 | 0 | |
| White Barbara | Chief Medical Officer | 206217 1.0662% | $798,059.79 | 27 | 0 | +9.31% |
| CATLIN AVERY W | director | 47000 0.243% | $181,890.00 | 5 | 0 | <0.0001% |
| Discordia Robert Paul | Chief Operating Officer | 35490 0.1835% | $137,346.30 | 3 | 0 | <0.0001% |
| Millian Craig Stuart | Chief Operating Officer | 27000 0.1396% | $104,490.00 | 8 | 0 | <0.0001% |
| HOLMER ALAN F | director | 22500 0.1163% | $87,075.00 | 3 | 0 | <0.0001% |
| GUPTA RENU | director | 15000 0.0776% | $58,050.00 | 3 | 0 | <0.0001% |
| Panayiotopoulos Paris | director | 14285 0.0739% | $55,282.95 | 1 | 0 | <0.0001% |
| Hochman David P | director | 7000 0.0362% | $27,090.00 | 14 | 0 | +5.91% |
$5,831,763 | 118 | -33.78% | $66.68M | |
Corbus Pharmaceuticals Holdings, Inc. (CRBP) | $9,405,928 | 107 | 12.61% | $74.85M |
$17,525,882 | 60 | 5.22% | $64.7M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$909,129 | 37 | 42.19% | $67.23M |
| Increased Positions | 53 | +58.89% | 6M | +64% |
| Decreased Positions | 33 | -36.67% | 1M | -13.72% |
| New Positions | 28 | New | 2M | New |
| Sold Out Positions | 10 | Sold Out | 368,031 | Sold Out |
| Total Postitions | 110 | +22.22% | 13M | +50.29% |
| Cormorant Asset Management, Lp | $18,691.00 | 13.19% | 2.38M | 0 | 0% | 2025-09-30 |
| Orbimed Advisors Llc | $9,226.00 | 6.51% | 1.17M | 0 | 0% | 2025-09-30 |
| Octagon Capital Advisors Lp | $8,775.00 | 6.19% | 1.11M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $4,817.00 | 3.4% | 612,030 | +12,535 | +2.09% | 2025-09-30 |
| Prosight Management, Lp | $2,703.00 | 1.91% | 343,400 | -236,493 | -40.78% | 2025-09-30 |
| Exome Asset Management Llc | $1,810.00 | 1.28% | 229,962 | -47,355 | -17.08% | 2025-09-30 |
| Blackrock, Inc. | $1,786.00 | 1.26% | 226,898 | -125,511 | -35.62% | 2025-09-30 |
| Comerica Bank | $1,574.00 | 1.11% | 200,001 | 0 | 0% | 2025-09-30 |
| Armistice Capital, Llc | $1,511.00 | 1.07% | 192,000 | 0 | 0% | 2025-09-30 |
| Aberdeen Group Plc | $1,481.00 | 1.05% | 188,231 | +116,005 | +160.61% | 2025-09-30 |